What does this research mean for the field?

Reducing the hydrophobic cavity within the trimeric RSV F protein stabilizes its prefusion conformation, yielding a disulfide-free vaccine candidate (RVF-88) that elicits potent, durable, and protective immunity against RSV in animal models. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To develop and evaluate a stabilized prefusion respiratory syncytial virus (RSV) F glycoprotein vaccine engineered by reducing the internal hydrophobic cavity without introducing disulfide bonds.

August 30, 2026EMBO Molecular MedicineOpen Access

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity

View Full Paper

Ask AI

Bookmark

Authors

LLLijie LiuFirst Affiliated Hospital of Guangzhou Medical University MYMengrong YanGuangzhou Experimental Station RLRuoxu LiangFirst Affiliated Hospital of Guangzhou Medical University

Discussion

Member takes

Implication

Preclinical study demonstrates durable protective immunity against RSV from a cavity-reduced prefusion F bivalent vaccine in animal models, highlighting a rational stabilization strategy.

Key Points

To develop and evaluate a stabilized prefusion respiratory syncytial virus (RSV) F glycoprotein vaccine engineered by reducing the internal hydrophobic cavity without introducing disulfide bonds.
Engineered the disulfide-free prefusion F immunogen RVF-88 using structure-guided cavity reduction at metastability-associated sites.
Evaluated antigen structural stability, in vitro neutralization, and in vivo protection using unadjuvanted bivalent formulations in mouse and cotton rat challenge models.
Structural analyses demonstrated reduced apical hydrophobic cavity volume and surface area while fully retaining prefusion architecture and key neutralizing epitopes, including antigenic site Ø.
Unadjuvanted bivalent RVF-88 elicited high neutralizing antibody titers and durable protective immunity lasting up to 5 months in mice, while providing complete protection against RSV challenge in both mice and cotton rats.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6a93f1176c1a8fb52e79dd02 https://doi.org/10.1038/s44321-026-00511-8

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates durable protective immunity against RSV from a cavity-reduced prefusion F bivalent vaccine in animal models, highlighting a rational stabilization strategy.

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity

Discussion

Member takes

Implication

Key Points

Cite This Study

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider